http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 08 Jun 2026 08:36:00 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++POS+EX+++++Galmed+Pharmaceuticals+++++++++++++++/26614841.html si-local-file:///var/storage/secattach/20260608/26614841.html http://www.streetinsider.com/SEC+Filings/Form++POS+EX+++++Galmed+Pharmaceuticals+++++++++++++++/26614841.html Mon, 08 Jun 2026 08:36:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++POS+EX+++++Galmed+Pharmaceuticals+++++++++++++++/26614841.html si-local-file:///var/storage/secattach/20260608/26614841.html http://www.streetinsider.com/SEC+Filings/Form++POS+EX+++++Galmed+Pharmaceuticals+++++++++++++++/26614841.html Mon, 08 Jun 2026 08:36:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Galmed+Pharmaceuticals+++++++++++++++/26614824.html si-local-file:///var/storage/secattach/20260608/26614824.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Galmed+Pharmaceuticals+++++++++++++++/26614824.html Mon, 08 Jun 2026 08:33:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Galmed+Pharmaceuticals+++++++++++++++/26614824.html si-local-file:///var/storage/secattach/20260608/26614824.html http://www.streetinsider.com/SEC+Filings/Form++424B3++++++Galmed+Pharmaceuticals+++++++++++++++/26614824.html Mon, 08 Jun 2026 08:33:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jun+08/26614703.html si-local-file:///var/storage/secattach/20260608/26614703.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jun+08/26614703.html Mon, 08 Jun 2026 08:26:00 -0400 GLMD O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jun+08/26614703.html si-local-file:///var/storage/secattach/20260608/26614703.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jun+08/26614703.html Mon, 08 Jun 2026 08:26:00 -0400 GLMD O.16140983 http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced it has entered into a definitive agreement to acquire Colospan Ltd., a medical device company focused on colorectal surgery solutions, for $4.5 million.</p> <p>The transaction includes $2.5 million in cash and $2.0 million in Galmed ordinary shares at closing, subject to customary adjustments and escrow provisions. Both companies' boards of directors have unanimously approved the deal, which is expected to close in the second quarter of 2026.</p> <p>Colospan's primary product, the CG-100 intraluminal bypass device, has received FDA Breakthrough Device Designation and is CE marked under the EU's Medical Device Regulation. The device is designed to http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html Mon, 08 Jun 2026 08:11:29 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced it has entered into a definitive agreement to acquire Colospan Ltd., a medical device company focused on colorectal surgery solutions, for $4.5 million.</p> <p>The transaction includes $2.5 million in cash and $2.0 million in Galmed ordinary shares at closing, subject to customary adjustments and escrow provisions. Both companies' boards of directors have unanimously approved the deal, which is expected to close in the second quarter of 2026.</p> <p>Colospan's primary product, the CG-100 intraluminal bypass device, has received FDA Breakthrough Device Designation and is CE marked under the EU's Medical Device Regulation. The device is designed to http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html Mon, 08 Jun 2026 08:11:29 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced it has entered into a definitive agreement to acquire Colospan Ltd., a medical device company focused on colorectal surgery solutions, for $4.5 million.</p> <p>The transaction includes $2.5 million in cash and $2.0 million in Galmed ordinary shares at closing, subject to customary adjustments and escrow provisions. Both companies' boards of directors have unanimously approved the deal, which is expected to close in the second quarter of 2026.</p> <p>Colospan's primary product, the CG-100 intraluminal bypass device, has received FDA Breakthrough Device Designation and is CE marked under the EU's Medical Device Regulation. The device is designed to http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html Mon, 08 Jun 2026 08:11:29 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced it has entered into a definitive agreement to acquire Colospan Ltd., a medical device company focused on colorectal surgery solutions, for $4.5 million.</p> <p>The transaction includes $2.5 million in cash and $2.0 million in Galmed ordinary shares at closing, subject to customary adjustments and escrow provisions. Both companies' boards of directors have unanimously approved the deal, which is expected to close in the second quarter of 2026.</p> <p>Colospan's primary product, the CG-100 intraluminal bypass device, has received FDA Breakthrough Device Designation and is CE marked under the EU's Medical Device Regulation. The device is designed to http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html Mon, 08 Jun 2026 08:11:29 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced it has entered into a definitive agreement to acquire Colospan Ltd., a medical device company focused on colorectal surgery solutions, for $4.5 million.</p> <p>The transaction includes $2.5 million in cash and $2.0 million in Galmed ordinary shares at closing, subject to customary adjustments and escrow provisions. Both companies' boards of directors have unanimously approved the deal, which is expected to close in the second quarter of 2026.</p> <p>Colospan's primary product, the CG-100 intraluminal bypass device, has received FDA Breakthrough Device Designation and is CE marked under the EU's Medical Device Regulation. The device is designed to http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html Mon, 08 Jun 2026 08:11:29 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html <p>Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) announced it has entered into a definitive agreement to acquire Colospan Ltd., a medical device company focused on colorectal surgery solutions, for $4.5 million.</p> <p>The transaction includes $2.5 million in cash and $2.0 million in Galmed ordinary shares at closing, subject to customary adjustments and escrow provisions. Both companies' boards of directors have unanimously approved the deal, which is expected to close in the second quarter of 2026.</p> <p>Colospan's primary product, the CG-100 intraluminal bypass device, has received FDA Breakthrough Device Designation and is CE marked under the EU's Medical Device Regulation. The device is designed to http://www.streetinsider.com/Mergers+and+Acquisitions/Galmed+to+acquire+Colospan+for+%244.5+million+in+medical+device+deal/26614661.html Mon, 08 Jun 2026 08:11:29 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/Press+Releases/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html <div class="xn-content"> <ul type="disc"><li>Transaction will add FDA Breakthrough Device-Designated technology with active <location value="LC/us" idsrc="xmltag.org" >U.S</location>. pivotal IDE trial, positioning Galmed to address one of colorectal surgery's most serious unmet needs.</li><li>Colospan's CG-100 Intraluminal Bypass Device, is CE marked under EU's Medical Device Regulation ("MDR") and ready for commercial launch in the EU and <location value="LC/il" idsrc="xmltag.org" >Israel</location>. Galmed contemplates an investment of <money>$6 million</money> to launch Colospan's device during H2 2026 in <location value="LR/eur" idsrc="xmltag.org" >Europe</location> with an initial focus on <location value="LC/de" idsrc="xmltag.org" >Germany</location>, <location value="LC/at" idsrc="xmltag.org" >Austria</location> and <location value="LC/ch" idsrc="xmltag.org" >Switzerland</location>.</li><li>Upon closing, Colospan will become a wholly owned http://www.streetinsider.com/PRNewswire/Galmed+Pharmaceuticals+to+Acquire+Colospan+to+Create+a+GI-Focused+Platform+Targeting+a+%246+Billion+Market/26614660.html Mon, 08 Jun 2026 08:10:00 -0400 A.01857600 A.50216913 GLMD O.00080482 O.13816658 O.16140983 http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jun+02/26587583.html si-local-file:///var/storage/secattach/20260602/26587583.html http://www.streetinsider.com/SEC+Filings/Form++6-K++++++++Galmed+Pharmaceuticals++++For%3A+Jun+02/26587583.html Tue, 02 Jun 2026 07:58:00 -0400 GLMD O.16140983